Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)

This study has been completed.
University of Maryland Greenebaum Cancer Center
Information provided by (Responsible Party):
howard safran, Brown University Identifier:
First received: August 28, 2007
Last updated: June 26, 2014
Last verified: June 2014
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001

Condition Intervention Phase
Esophageal Cancer
Drug: PPX with cisplatin and radiation
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001

Resource links provided by NLM:

Further study details as provided by Brown University:

Primary Outcome Measures:
  • Complete Pathologic Response [ Time Frame: At Surgery approximately 4weeks after last treatment ]
    Per pathology review post surgery

Enrollment: 40
Study Start Date: August 2007
Study Completion Date: April 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PPX with cisplatin and radiation
PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
Drug: PPX with cisplatin and radiation
weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
Other Name: Paclitaxel Poliglumex, Cisplatin and radiation

Detailed Description:
32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4 Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin weekly times 6 followed by surgery.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction
  • Patients may have celiac adenopathy
  • There must be no evidence of distant organ metastases
  • No prior chemotherapy or radiation for esophageal cancer
  • Patients must be > 18 years of age, and non pregnant
  • Patients must have an ANC > 1,500/ul, platelets > 100,000/ul, creatinine < 2.0 and bilirubin < 1.5 x ULN-ECOG performance status 0-1.
  • Female patients, must either be not of child bearing potential or have a negative pregnancy test within 14 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible
  • No contraindications to esophagectomy
  • Signed informed consent

Exclusion Criteria:

  • Active or uncontrolled infection
  • Patients must not have other coexistent medical condition that would preclude protocol therapy.
  • Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00522795

United States, Rhode Island
Lifespan Hospitals
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Brown University
University of Maryland Greenebaum Cancer Center
Principal Investigator: Howard Safran, MD Brown University
  More Information

Responsible Party: howard safran, Principle Investigator, Brown University Identifier: NCT00522795     History of Changes
Other Study ID Numbers: BrUOG-E-215
Study First Received: August 28, 2007
Results First Received: May 21, 2013
Last Updated: June 26, 2014

Keywords provided by Brown University:
Esophageal Cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017